Abstract

This IDC study focuses on a combination of RBM technology and consulting solutions. This IDC MarketScape provides a qualitative and quantitative assessment based on criteria that should be important to life science companies when considering the selection of a strategic RBM solution provider to help provide guidance for strategic, operational, and tactical transformation issues within the RBM-RBQM space, as well as technology platforms, and build capabilities. This is the first time that an IDC MarketScape assessment of RBM solutions for life science R&D has been performed.

Dr. Nimita Limaye, research VP, Life Science R&D Strategy and Technology at IDC, noted, "The differentiator for great enterprises is not the amount of data that they have but the intelligence that they extract from it to minimize study risk, enhance data quality, and drive patient safety. The future of intelligence for clinical trials encompasses effectively leveraging an RBQM strategy, deeply embedding a QbD approach within the organization's DNA, building a quality-centric culture, and optimizing the use of technology solutions to develop an agile, predictive, prescriptive, and a proactive strategy to managing risks."

Coverage